Eli Lilly and Company $LLY is Weatherly Asset Management L. P.’s Largest Position

by · The Cerbat Gem

Weatherly Asset Management L. P. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 285,346 shares of the company’s stock after selling 498 shares during the period. Eli Lilly and Company accounts for 17.9% of Weatherly Asset Management L. P.’s portfolio, making the stock its biggest holding. Weatherly Asset Management L. P.’s holdings in Eli Lilly and Company were worth $217,719,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Sumitomo Mitsui Financial Group Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $27,000. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. lifted its stake in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Financial Gravity Companies Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth $31,000. Finally, Bare Financial Services Inc increased its stake in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LLY. BMO Capital Markets set a $1,200.00 price objective on Eli Lilly and Company in a research report on Thursday, December 4th. UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a research report on Thursday, December 18th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. The Goldman Sachs Group upped their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, HSBC reiterated a “hold” rating and set a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

Get Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 0.0%

LLY opened at $1,077.26 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s fifty day moving average is $986.75 and its two-hundred day moving average is $841.37. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.70, a PEG ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).